Research ArticleMetabolism

SerpinB13 antibodies promote β cell development and resistance to type 1 diabetes

See allHide authors and affiliations

Science Translational Medicine  07 Apr 2021:
Vol. 13, Issue 588, eabf1587
DOI: 10.1126/scitranslmed.abf1587

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Dismantling a barrier to β cell development

Autoantibodies to the protease inhibitor serpinB13 have previously been linked to delayed onset of type 1 diabetes (T1D) in humans. Now, Kryvalap et al. show using mouse pancreatic explant cultures that the protease inhibitor serpinB13 regulates the Notch signaling involved in pancreatic development. Mouse models of T1D exposed to anti-serpinB13 antibody during development showed increased numbers of pancreatic progenitor cells along with ameliorated pancreatic islet cell development. This study suggests that serpinB13 could potentially be a therapeutic target in children with T1D.

View Full Text

Stay Connected to Science Translational Medicine